Gilead Sciences Inc (XTER:GIS)
€ 114.1 -0.76 (-0.66%) Market Cap: 143.26 Bil Enterprise Value: 155.94 Bil PE Ratio: 17.90 PB Ratio: 6.94 GF Score: 82/100

Gilead Sciences Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 19, 2026 / 03:00PM GMT
Brian Abrahams
RBC Capital Markets Inc - Managing Director

Welcome back, everyone. I'm Brian Abrahams, senior biotech analyst here at RBC Capital Markets. We're really pleased to have our next featured company, Gilead Sciences, represented by their Chief Medical Officer, Dietmar Berger.

Dietmar, thanks again for joining us.

Dietmar Berger
Gilead Sciences, Inc - Chief Medical Officer

Yes. Thanks for having us. Pleasure to be here.

Questions & Answers

Brian Abrahams
RBC Capital Markets Inc - Managing Director

So a lot to cover. So I'll kick it off and maybe just start with Trodelvy because I know we're going to see a big data point this year on EVOKE-03. Can you talk a little bit more about, I guess, what you're looking for out of those results? In particular, what specific efficacy thresholds on PFS or OS do you think this trial would need to show in order to justify the positioning of a TROP2 ADC in frontline? How are you thinking about the competitive landscape overall here?

And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot